There is no question that India is now the source of most of the drugs that are providing antiretroviral treatment around the world, and overwhelmingly the source for drugs in Africa. They're being used increasingly even by the American presidential initiative.They're being used by the Global Fund to Fight AIDS, Tuberculosis and Malaria. They're being used by the Clinton Foundation. They form the basis for most of the treatment, but it's not endless. They have production limitations, and there is some uncertainty as to the nature of the amendments to the Patent Act in India whether those drugs can continue to be produced in such large quantums.
There is also the question of the second-line drugs, which are desperately needed, and for whom the downward price negotiation has not yet occurred. And indeed the flow is not guaranteed.
So there is always room, there would absolutely be room for Canadian legislation, manufacture, and export. There is no question about it—and the demand, given the huge numbers that are required. And it looks as though, relatively speaking, we could compete. It might be a matter of a few cents either way.